Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature

Autoimmunity Reviews

Volumn 10, Issue 11, 2011, Pages 679-684

  Pons Estel, Guillermo J ^a   Salerni, Gabriel E ^a   Serrano, Rosa M ^a   Gomez Puerta, José A ^a   Plasin, Miguel A ^a   Aldasoro, Edelweiss ^a   Lozano, Miguel ^a   Cid, Joan ^a   Cervera, Ricard ^a   Espinosa, Gerard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Refractory disease; Systemic autoimmune diseases; Therapeutic plasma exchange

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CRYOGLOBULINEMIA; DERMATOMYOSITIS; FEMALE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PLASMAPHERESIS; POLYARTERITIS NODOSA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TERTIARY HEALTH CARE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80052266994     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.028     Document Type: Review

References (63)

1. McCarthy L.J. The challenge of evidence-based medicine for apheresis. Ther Apher Dial. 2003, 7:153-154.
2. Madore F., Lazarus J.M., Brady H.R. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol. 1996, 7:367-386.
3. Smith J.W., Weinstein R., Hillyer K.L. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion (Paris). 2003, 43:820-822.
4. Szczepiorkowski Z.M., Winters J.L., Bandarenko N., Kim H.C., Linenberger M.L., Marques M.B., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. Journal of clinical apheresis. 2010, 25:83-177.
5. Clark W.F., Rock G.A., Buskard N., Shumak K.H., LeBlond P., Anderson D., et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med. 1999, 131:453-462.
6. Klein H.G., Balow J.E., Dau P.C., Hamburger M.I., Leitman S.F., Pineda A.A., et al. Clinical applications of therapeutic apheresis. Report of the Clinical Applications Committee, American Society for Apheresis. J Clin Apher. 1986, 3:1-92. i-vi.
7. Zucchelli P., Pasquali S., Cagnoli L., Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988, 33:1175-1180.
8. Rock G.A., Shumak K.H., Buskard N.A., Blanchette V.S., Kelton J.G., Nair R.C., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991, 325:393-397.
9. Yokoyama H., Wada T., Zhang W., Yamaya H., Asaka M. Advances in apheresis therapy for glomerular diseases. Clin Exp Nephrol. 2007, 11:122-127.
10. Lockwood C.M., Worlledge S., Nicholas A., Cotton C., Peters D.K. Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med. 1979, 300:524-530.
11. Casian A., Jayne D. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr Opin Rheumatol. 2011, 23:12-17.
12. Geltner D., Kohn R.W., Gorevic P., Franklin E.C. The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement. Arthritis Rheum. 1981, 24:1121-1127.
13. Ferri C., Gremignai G., Bombardieri S., Moriconi L., Pontrandolfo A., Vitali C., et al. Plasma-exchange in mixed cryoglobulinemia. Effects on renal, liver and neurologic involvement. International Journal of Clinical & Laboratory Research. 1986, 16:403-411.
14. Stefanutti C., Vivenzio A., Di Giacomo S., Labbadia G., Mazza F., D'Alessandri G., et al. Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia. J Clin Apher. 2009, 24:241-246.
15. Russo G.E., Caramiello M.S., Vitaliano E., De Marco C.M., Pennacchia M., Giusti S., et al. Haemorheological changes in mixed cryoglobulinaemia during apheresis treatment. Transfus Sci. 1996, 17:499-503.
16. Pietrogrande M., Devita S., Zignego A., Pioltelli P., Sansonno D., Sollima S., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in Hepatitis C virus-infected patients. Autoimmun Rev 2011.
17. Gomez-Puerta J.A., Hernandez-Rodriguez J., Lopez-Soto A., Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest. 2009, 136:1101-1111.
18. Lee R.W., D'Cruz D.P. Pulmonary renal vasculitis syndromes. Autoimmun Rev. 2010, 9:657-660.
19. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007, 18:2180-2188.
20. de Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R., Jayne D.R., Gaskin G., Rasmussen N., et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2007, 18:2189-2197.
21. Walsh M., Catapano F., Szpirt W., Thorlund K., Bruchfeld A., Guillevin L., et al. plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis. 2010.
22. Rifle G., Chalopin J.M., Zech P., Deteix P., Ducret F., Vialtel P., et al. Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study. Proc Eur Dial Transplant Assoc. 1981, 18:493-502.
23. Szpirt W., Rasmussen N., Petersen J. Long term outcome and prognostic factors in randomized study of plasma exchange and cyclosporine A in Wegeners granulomatosis. J Am Soc Nephrol. 1999, 10:A1.
24. Zauner I., Bach D., Braun N., Kramer B.K., Funfstuck R., Helmchen U., et al. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis. 2002, 39:28-35.
25. Mauri J., Gonzales M.T., Poveda R. Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis. Plasma Ther Transfus Technol 1985, 587-591.
26. Guillevin L., Cevallos R., Durand-Gasselin B., Lhote F., Jarrousse B., Callard P. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris). 1997, 148:198-204.
27. Glockner W.M., Sieberth H.G., Wichmann H.E., Backes E., Bambauer R., Boesken W.H., et al. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. Clin Nephrol. 1988, 29:1-8.
28. Pusey C.D., Rees A.J., Evans D.J., Peters D.K., Lockwood C.M. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991, 40:757-763.
29. Cole E., Cattran D., Magil A., Greenwood C., Churchill D., Sutton D., et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis. 1992, 20:261-269.
30. Szpirt W.M., Heaf J.G., Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis - a clinical randomized controlled trial. Nephrol Dial Transplant. 2011, 26:206-213.
31. Espinosa G., Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nature reviews. 2010, 6:296-300.
32. Cervera R., Bucciarelli S., Plasin M.A., Gomez-Puerta J.A., Plaza J., Pons-Estel G., et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun. 2009, 32:240-245.
33. Cervera R., Espinosa G., Bucciarelli S., Gomez-Puerta J.A., Font J. Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Rev. 2006, 6:81-84.
34. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006, 6:98-103.
35. Espinosa G., Bucciarelli S., Cervera R., Lozano M., Reverter J.C., de la Red G., et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004, 63:730-736.
36. Marson P., Bagatella P., Bortolati M., Tison T., De Silvestro G., Fabris F., et al. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. J Intern Med. 2008, 264:201-203.
37. El-Haieg D.O., Zanati M.F., El-Foual F.M. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J_Gynaecol Obstet. 2007, 99:236-241.
38. Ruffatti A., Marson P., Pengo V., Favaro M., Tonello M., Bortolati M., et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev. 2007, 6:196-202.
39. Szczepiorkowski Z.M., Bandarenko N., Kim H.C., Linenberger M.L., Marques M.B., Sarode R., et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2007, 22:106-175.
40. Szczepiorkowski Z.M., Shaz B.H., Bandarenko N., Winters J.L. The new approach to assignment of ASFA categories-introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher. 2007, 22:96-105.
41. Wei N., Klippel J.H., Huston D.P., Hall R.P., Lawley T.J., Balow J.E., et al. Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet. 1983, 1:17-22.
42. Schroeder J.O., Euler H.H. Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv Exp Med Biol. 1989, 260:203-213.
43. Bambauer R., Schwarze U., Schiel R. Cyclosporin A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus. Artif Organs. 2000, 24:852-856.
44. Neuwelt C.M. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial. 2003, 7:173-182.
45. Lewis E.J., Hunsicker L.G., Lan S.P., Rohde R.D., Lachin J.M. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med. 1992, 326:1373-1379.
46. Euler H.H., Schroeder J.O., Harten P., Zeuner R.A., Gutschmidt H.J. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum. 1994, 37:1784-1794.
47. Wallace D.J., Goldfinger D., Pepkowitz S.H., Fichman M., Metzger A.L., Schroeder J.O., et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher. 1998, 13:163-166.
48. Danieli M.G., Palmieri C., Salvi A., Refe M.C., Strusi A.S., Danieli G. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher. 2002, 17:72-77.
49. Flanc R.S., Roberts M.A., Strippoli G.F., Chadban S.J., Kerr P.G., Atkins R.C. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2004, 43:197-208.
50. Mok C.C. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum. 2006, 36:71-81.
51. Klaiman M.D., Miller S.D. Transverse myelitis complicating systemic lupus erythematosus: treatment including hydroxychloroquine. Case report. Am J Phys Med Rehabil. 1993, 72:158-161.
52. Kimura K.Y., Seino Y., Hirayama Y., Aramaki T., Yamaguchi H., Amano H., et al. Systemic lupus erythematosus related transverse myelitis presenting longitudinal involvement of the spinal cord. Intern Med. 2002, 41:156-160.
53. Kovacs B., Lafferty T.L., Brent L.H., DeHoratius R.J. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000, 59:120-124.
54. Dau P.C. Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients. Arch Neurol. 1981, 38:544-552.
55. Miller F.W., Leitman S.F., Cronin M.E., Hicks J.E., Leff R.L., Wesley R., et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992, 326:1380-1384.
56. Cherin P., Auperin I., Bussel A., Pourrat J., Herson S. Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases. Clin Exp Rheumatol. 1995, 13:270-271.
57. Braun-Moscovici Y., Furst D.E. Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it?. Curr Opin Rheumatol. 2003, 15:197-204.
58. Le Guern V., Guillevin L. Therapeutic apheresis for myositises. Transfus Apher Sci. 2007, 36:169-172.
59. Choy E.H., Hoogendijk J.E., Lecky B., Winer J.B., Gordon P. WITHDRAWN: immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2009, CD003643.
60. Cozzi F., Marson P. Plasma-exchange in the treatment of systemic rheumatic diseases: past and present experience. Reumatismo. 2009, 61:161-164.
61. Guillevin L., Pagnoux C. Indication for plasma exchange for systemic necrotizing vasculidities. Transfus Apher Sci. 2007, 36:179-185.
62. Guillevin L., Lhote F., Gayraud M., Cohen P., Jarrousse B., Lortholary O., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996, 75:17-28.
63. Pagnoux C., Mahr A., Cohen P., Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005, 84:115-128.